Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

The conversation discusses the potential of Replicel/Shiseido treatment for hair loss, questioning its effectiveness, whether it grows new follicles, and its market release timeline. It also compares Replicel to other competitors like Kyocera/RIKEN/Tsuji.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

The conversation is about skepticism towards a hair serum advertised on Instagram, with users doubting its effectiveness and one sharing a personal negative experience with the product.

The conversation discusses improvements to a platform and mentions hair loss treatments including Minoxidil, finasteride, RU58841, and melatonin. It also highlights the addition of features like Google login, reply by email, keyword extraction, and a term glossary for better understanding of hair-related terminologies.

The user is using a hair loss treatment regimen that includes RU58841, minoxidil mixed with finasteride, adenosine, dermarolling with lidocaine cream, and biotin. They are questioning if they are dermarolling too aggressively and are willing to accept baldness if no improvement is seen in 6 months.

The conversation is about enhancing dermarolling for hair loss by using topical peptides like tb-500 or GHK-Cu to aid in healing and hair growth, and whether anyone has experienced significant results from this method.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references upcoming trial data from Shiseido in Japan.

A TikTok trend promoting a roll-on hair regrowth pen is discussed, with skepticism about its effectiveness without using finasteride or dutasteride. The original poster has been using finasteride for 2 years, minoxidil for 1 year, and microneedling for 12 months.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

The conversation humorously discusses the journey of deciding to use finasteride for hair loss, with a focus on a funny Facebook post. It also touches on the idea of promoting finasteride use to future generations.

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.

This post and conversation are about using receipt paper as a satirical treatment for hair loss. Users humorously discuss various absurd methods, including rubbing, ingesting, and making suppositories out of receipts.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

User shares 2-month progress with fin, min, dermarolling. Others discuss consistency, regrowth, shedding, and potential side effects.

The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.

The conversation is about someone's three-year experience with irregular derma rolling, Minoxidil, and Redensyl for hair loss, hoping to thicken areas with fine hair.

The conversation discusses arranging an interview with the developers of RU58841 to clarify its safety and reasons for halted research, with some users expressing concerns about potential risks and others citing financial reasons for the discontinuation of studies. Specific treatments mentioned include RU58841, minoxidil, and finasteride.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

A user's 1 year update on hair loss treatments, including minoxidil, nizoral and derma rolling; with comments from other users praising the results of the treatments.